Incentives for orphan drug research and development in the United States

Orphanet Journal of Rare Diseases

Volumn 3, Issue 1, 2008, Pages

  Seoane Vazquez, Enrique ^a   Rodriguez Monguio, Rosa ^b   Szeinbach, Sheryl L ^a   Visaria, Jay ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ORPHAN DRUG;

ARTICLE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; REWARD; UNITED STATES; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMICS; EVALUATION; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MOTIVATION; NEOPLASM; PATENT; RARE DISEASE; RESEARCH; STATISTICS;

DRUG APPROVAL; DRUG INDUSTRY; HEALTH POLICY; HUMANS; MOTIVATION; NEOPLASMS; ORPHAN DRUG PRODUCTION; PATENTS AS TOPIC; RARE DISEASES; RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 60749114770     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-3-33     Document Type: Article

References (26)

1. The Orphan Drug Regulations. United States Food and Drug Administration, Final rule, 57 FR 62076. 21 CFR Part 316 1992
2. The Orphan Drug Act. The first 7-years. CH Asbury, JAMA 1991 265 893 7 10.1001/jama.265.7.893 1992188
3. Office of Rare Diseases. National Institutes of Health, 2008 http://rarediseases.info.nih.gov (Accessed January 30, 2008).
4. Rare diseases act of 2002. Public Law 107-280. United States Congress, http://www.history.nih.gov/01docs/historical/documents/PL107-280.pdf (Accessed January 3, 2008).
5. The Orphan Drug Act implementation and impact. Office of Inspector General. United States Department of Health and Human Services, 2001 http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf (Accessed January 3, 2008).
6. A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. M Wastfelt B Fadeel J-I Henter, Journal of Internal Medicine 2006 260 1 10 10.1111/j.1365-2796.2006.01666.x 16789973
7. Information on the OOPD grant program. United States Food and Drug Administration, 2008 (Accessed January 3, 2008).
8. Two decades of orphan drug development. ME Haffner J Whitley M Moses, Nature Rev Drug Discovery 2002 1 821 5 10.1038/nrd919
9. The Orphan Drug Act: an engine of innovation? At what cost? DD Rohde, Food Drug Law J 2000 55 1 125 143 12322720
10. The U.S. orphan drug program 1983-1995. SR Shulman M Manocchia, PharmacoEconomics 1997 12 312 26 10170457
11. Adopting orphan drugs: Two dozen years of treating rare diseases. ME Haffner, The New Eng J of Med 2006 354 445 7 10.1056/NEJMp058317
12. Drug patent life and generic entry: Analysis of the new molecular entities approved by the FDA between 1980 and 1999. E Seoane-Vazquez S Schondelmeyer SL Szeinbach, J of Pharmaceutical Finance, Econ and Policy 2008 16 67 85
13. List of orphan designations and approvals. United States Food and Drug Administration, 2008 http://www.fda.gov/orphan/designat/list.htm May 16, 2008. (Accessed June 20, 2008).
14. Market incentives and pharmaceutical innovation. W Yin, J of Health Econ 2008 27 1060 1077 10.1016/j.jhealeco.2008.01.002
15. pharmaceutical R&D: costs, risks, and rewards. Office of technology assessment, United States Congress, Washington, DC: U.S. Government Printing Office 1993 http://www.princeton.edu/∼ota/disk1/1993/9336-n.html (Accessed January 3, 2008).
16. Orphan drugs development and some methods for maximizing the usefulness of research on rare diseases. MJ Finkel, Cooperative approaches to research and development of orphan drugs. Proceedings of a Conference held in April 9-10, 1984 New York: Alan R. Liss, Inc, Van Woert MH, Chung E, 1985 11 18
17. The economics of orphan drug policy in the U.S.: Can the legislation be improved? JW Peabody A Ruby P Cannon, PharmacoEconomics 1995 8 374 84 10160072
18. House Committee on Energy and Commerce. Subcommittee on Health and the Environment. Preliminary report of the survey on drugs for rare diseases. Prepared for the subcommittee on health and the environment, committee on energy and commerce. United States Congress, Washington: U.S. Government Printing Office 1982
19. Small business innovation research (SBIR) and small business technology transfer (STTR) programs. National Institutes of Health, 2007 http://grants.nih.gov/grants/funding/sbirsttr-programs.htm updated: 5/1/2007 (Accessed January 3, 2008).
20. Evaluation of orphan drugs by the U.S. food and drug administration. ME Haffner JV Kelsey, International J of Technology Assessment in Health Care 1992 8 647 57
21. National Health Spending In 2006: A Year Of Change For Prescription Drugs. A Catlin C Cowan M Hartman S Heffler, Health Aff 2008 27 1 14 29 10.1377/hlthaff.27.1.14
22. The development of orphan drugs: A pharmaceutical company perspective. JC Stucki, Cooperative approaches to research and development of orphan drugs. Proceedings of a Conference held in April 9-10, 1984 New York: Alan R. Liss, Inc, Van Woert MH, Chung E, 1985 95 104
23. A model of effective health policy: The 1983 orphan drug act. ND Reaves, J of Health & Soc Pol 2003 17 61 71 10.1300/J045v17n04-04
24. The development of orphan drugs. MJ Finkel, The New Eng J of Med 1982 307 963 4
25. Grabowski HG. Economics of new oncology drug development. JA DiMasi, J Clin Oncol 2007 25 209 216 10.1200/JCO.2006.09.0803 17210942
26. Prescription for the orphan drug act: The impact of the FDA's 1992 regulations and the latest congressional proposals for reform. DB Clissold, Food Drug Law J 1995 50 1 125 47 10342989